Blue states call on FDA to expand abortion pill access
The joint petition, filed Thursday, comes days after FDA Commissioner Marty Makary committed to reviewing the abortion drug amid pressure from Department of Health and Human Services Secretary Robert F. Kennedy Jr. and some Republican lawmakers.
The FDA first approved of the use of mifepristone and misoprostol for an abortion in 2000.
Unlike surgical abortions, medication abortions do not need to take place in a clinical setting, and patients are able to take the pills at home.
Most abortions in the U.S. are now medication abortions, according to data from the reproductive health and rights group Guttmacher Institute. In 2023, 63 percent of all abortions in the U.S. were medication abortions.
The safety of mifepristone has come under increased scrutiny by some Republican lawmakers, citing a flawed study claiming the rate of adverse health events that occur among patients is far higher than previously reported.
More than 100 scientific studies have been conducted looking at the safety and efficacy of mifepristone and misoprostol; all of them have found that the drugs are a safe way to terminate a pregnancy.
'Given Mifepristone's 25-year safety record, there is simply no scientific or medical reason to subject it to such extraordinary restrictions,' New York Attorney General Letitia James said. 'The FDA must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care.'
Mifepristone's use is subject to a Risk Evaluation and Mitigation Strategy (REMS) program under the FDA. The attorneys general argue three requirements under the REMS program for the drug should be removed since they pose a burden to patients and health care systems.
The first is related to prescriber certification. As part of the REMS program, health care providers who prescribe mifepristone are required to add their names to national and abortion provider lists, which the attorneys general say raise 'serious safety and legal concerns.'
The second has to do with patient agreement forms. All patients who want mifepristone — even those using the drug to treat a miscarriage — are required to sign a document stating they are using the drug to end a pregnancy.
The third requirement mentioned in the petition is connected to pharmacy certification. As part of mifepristone's REMS program, pharmacies that carry the drug are subject to tracking, shipping and reporting requirements, which the attorneys general argue may 'dissuade' some from carrying the drug.
The FDA has yet to reply to a request for comment from The Hill about the petition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
26 minutes ago
- Chicago Tribune
Doctors: 2025 will be the year of measles in North America. Why?
Looking back, 2025 may be characterized as 'the year of measles in North America.' The U.S. has recorded its highest number of measles cases in more than 30 years, although cases have tailed off significantly in the last eight weeks and are only slightly higher than they were in 2019. The current per capita incidence of measles in the U.S. is roughly 4 per 1 million people. While there is a cyclical component to measles every several years, declining vaccination rates are by far the largest factor in this increase. According to Johns Hopkins University, the average county-level vaccination rate in the U.S. for measles, mumps and rubella declined from 93.9% pre-pandemic to 91.3% post-pandemic, moving further away from the 95% herd immunity threshold necessary to limit the spread of measles. (There are actually far more people vaccinated in the U.S. than there were in 2000, when measles was 'eliminated' but the U.S. population has risen by 20% since then, and the number of unvaccinated has outpaced the population rise.) This is simply the latest illustration of the importance of vaccines. Even small decreases in vaccination rates can have big consequences. Which brings us to Health and Human Services Secretary Robert F. Kennedy Jr. and his fraught relationship with the mRNA vaccine, the unique delivery system that carries genetic material into the body's cells to create an immune response against viral proteins. Under Kennedy's guidance, HHS will gradually wind down its mRNA vaccine development programs and cancel 22 vaccine projects that have funding totaling $500 million. Some mRNA contracts in their final stages will be allowed to conclude, but no new mRNA projects will be put in place. The government is essentially getting out of the mRNA business. During the COVID-19 pandemic, Operation Warp Speed, the federal initiative to rapidly develop an mRNA vaccine for the coronavirus, saved thousands of lives in the U.S. and millions of lives worldwide. The immune response created by the vaccine conferred relative protection for those infected and the severity of COVID-19 infections gradually declined. Besides this, those vaccinated with the mRNA vaccine were at less risk of developing post-COVID-19 persistent fatigue and other physical problems, known as long COVID. Recent data from a national study led by Rush University in Chicago found that those who did develop long COVID returned to full employment with fewer financial hardships if they had been vaccinated. Not that the mRNA-powered COVID-19 vaccine was perfect. It decreased disease severity but did not prevent infection or transmission. The immunity it confers is short-lived, so patients must be revaccinated at frequent intervals. Side effects are rare, but heart inflammation in young men is not uncommon. Kennedy's oft-intemperate and sometimes-unscientific remarks about vaccines have generated fierce criticism from the public health community and much of the mainstream press. His critics have made equally intemperate remarks, suggesting that Kennedy will have the blood of millions on his hands. Not yet anyway, but it makes it difficult to analyze in sober fashion what Kennedy is doing. What he is doing is rolling the dice. The strength of mRNA technology was that it could be developed and modified quickly in comparison to other non-mRNA vaccine technologies (almost nobody expected the mRNA COVID-19 vaccine to be ready as soon as it was). Scrapping mRNA research means the country might be unprepared upon the arrival of the next pandemic — whether it is a new COVID-19 strain, bird flu or some other agent that requires a rapid response. Kennedy and his HHS minions are redirecting efforts toward what they hope are improved technologies. He seeks vaccines developed with more transparency that are safer and more durable and can address the shortcomings of mRNA vaccines. Maybe that will happen. Currently, other platforms include inactivated vaccines that use the actual organism to stimulate the immune system (flu vaccine); attenuated vaccines that use a weakened form of the organism to cause a mild infection (measles vaccine); and conjugate vaccines that use parts of the organism that don't cause infection but train the immune system to respond (meningitis vaccine). But developing and testing new platforms takes time, and the vaccines created may still underperform in real-world usage. Is Kennedy's move to abandon mRNA research a calculated risk or a rash one? No one — not experts, the media nor the public — can say with confidence because the future and the science are uncertain. The next pandemic may occur in a year, a decade or a generation. Answering that question will require patience, intellectual honesty, humility and wisdom. The Kennedy family has always walked the fine line between fantastic luck and accomplishment on one side and tragic misfortune on the other. Let's hope the Kennedy luck is with the country here. Dr. Cory Franklin is a retired intensive care physician and the author of 'The COVID Diaries 2020-2024: Anatomy of a Contagion as it Happened.' Dr. Robert Weinstein is an infectious disease specialist at Rush University Medical Center.
New York Times
an hour ago
- New York Times
I'm Conservative. My Disabled Son Needs Medicaid to Survive.
I'm a registered Republican who just watched her party spend much of the summer pushing through new cuts to Medicaid. I'm also here to tell you why I'm an unlikely supporter of the program. My son's life depends on government assistance. Recent cuts to Medicaid at both the federal and state levels mean millions of families like mine could soon be at a loss for how to care for our disabled loved ones. In February 2021, during a routine ultrasound appointment when I was 17 weeks pregnant with my third child, David, doctors discovered that he had a set of life-threatening fetal anomalies. Our boy had an excruciatingly rare midline cleft lip and palate and was missing critical portions of his brain. We were told he fit the profile for a baby that had trisomy 18 and trisomy 13, or a disorder called holoprosencephaly, when the brain fails to divide appropriately into separate hemispheres. The first days after David's diagnosis were otherworldly. Each subsequent day of my pregnancy was a nightmare. I became a person in pain. Expecting David to be stillborn, we were amazed when he was born at term. At the hospital, after M.R.I. scans revealed strange imbalances in the size of his brain, we were told to expect him to die from intractable seizures. To our surprise, we were eventually discharged. There was nothing more to do — no treatments, just waiting. I thought David would die overnight. But David lived. We celebrated his fourth birthday in July. I do not understand the course of his life; I am simply grateful. David does not walk, talk or eat independently. He is visually impaired and has hearing loss. He has an unrepaired cleft palate open to protruding brain tissue, covered by a thin layer of mucous membrane. Developmentally, David is like a 10-month-old baby. He is our joy, and it is our privilege to parent him. Caring for David is holy work, but it takes a village. His extensive medical conditions mean he meets the criteria for institutionalized care. But because of Medicaid, David is able to live at home, where he belongs, surrounded by people who love him. North Carolina's Community Alternatives Program for Children, or CAP/C, is a home- and community-based services waiver that provides essential services to more than 3,700 children like David across our state. Doctors' appointments, surgeries, many therapies, adaptive equipment, specialized food, medical supplies, respite care workers (who provide temporary relief to caregivers) and more are all provided for him by Medicaid. I am even paid a living wage to care for my son. David's life simply wouldn't be possible without this program — which keeps him healthy and alive. Medicaid is David's village. Want all of The Times? Subscribe.
Business Insider
3 hours ago
- Business Insider
Why Is EnVVeno Medical Stock (NVNO) Down 70% Today?
EnVVeno Medical (NVNO) stock took a beating after the medical device company's VenoValve surgical replacement venous valve for severe deep chronic venous insufficiency was rejected by the U.S. Food and Drug Administration (FDA). The FDA sent a non-approvable letter to EnVVeno Medical, stating it couldn't approve the Premarket Approval application for the product in its current form. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to EnVVeno Medical, the FDA wouldn't approve the medical device because 'the favorable revised Venous Clinical Severity Score (rVCSS) data generated by the study to show clinical improvement, together with the improvements in pain scores and venous specific quality of life indicators was not sufficient on its own to determine favorability of the benefit risk profile for the VenoValve.' EnVVeno Medical noted its disappointment with the FDA's decision and is weighing options, including a potential resubmission or appeal. The company also said that it will take into account what it has learned from this letter in its development of enVVe a non-surgical replacement venous valve that it plans to submit an IDE application for. EnVVeno Medical Stock Movement Today EnVVeno Medical stock was down 71.84% in pre-market trading, following a 16.12% drop yesterday. The shares were still up 38.74% year-to-date but were down 20.94% over the past 12 months. Today's news came with heavy trading, as some 3.6 million shares changed hands, compared to a three-month daily average of about 148,000 units. Is EnVVeno Medical Stock a Buy, Sell, or Hold? Turning to Wall Street, coverage of EnVVeno Medical is thin. Fortunately, TipRanks' AI analyst Spark has it covered. Spark rates NVNO stock a Neutral (58) with no price target. It cites 'robust technical performance, which is somewhat overshadowed by challenging financial metrics' as reasons for this stance.
